A 2014 study1 reported that autoimmune aquaporin 4 (AQP4) channelopathy was the most common cause of immune-mediated recurrent longitudinally extensive transverse myelitis (rLETM), with seropositivity in 42 of 47 cases (89%). Autoimmune myelin oligodendrocyte glycoproteinopathy (MOG-opathy) with serum antibodies targeting MOG (MOG-IgG) has recently been reported in AQP4-IgG seronegative longitudinally extensive transverse myelitis (LETM).2 Another autoimmune astrocytopathy with glial fibrillary acidic protein (GFAP-IgG) as a biomarker may include myelitis sometimes longitudinally extensive as a component of a meningoencephalomyelitis.3 We present additional serological data with regard to 2 novel glial targets (MOG and GFAP) in patients with rLETM.
Jitprapaikulsan J, Lopez Chiriboga AS, Flanagan EP, et al. Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis. JAMA Neurol. 2018;75(7):892–895. doi:10.1001/jamaneurol.2018.0805
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: